Shukra Pharmaceuticals to hold 33rd AGM on Sep 28, 2026, to approve FY26 results and declare dividend
Shukra Pharmaceuticals Limited will hold its 33rd AGM on September 28, 2026, via Video Conference. The agenda includes adopting FY26 financial statements and approving a 1% final dividend. Ms. Sanskruti Patel's re-appointment as Director and Mr. Dinesh Chauhan's regularization as Independent Director are also on the agenda.
The announcement pertains to a scheduled AGM with routine agenda items and does not involve any new strategic initiatives, financial performance changes, or major corporate actions that would significantly impact the company's stock.
The announcement is a routine corporate communication regarding an upcoming AGM and does not contain any significant positive or negative financial news.
Shukra Pharmaceuticals Limited has announced the notice for its 33rd Annual General Meeting (AGM), scheduled to be held on Monday, September 28, 2026, at 12:00 P.M. (IST) through Video Conferencing (VC).
The AGM will focus on several key businesses including the consideration and adoption of the audited financial statements for the Financial Year ended March 31, 2026, along with the reports of the Board of Directors and Auditors.
Furthermore, the shareholders will be asked to approve and declare a final dividend of 1% (₹0.01 per equity share of ₹1 each) for the financial year 2025-26, as recommended by the Board of Directors. The meeting will also address the re-appointment of Ms. Sanskruti Patel as a Director (Executive) and the regularization of Mr. Dinesh Chauhan as a Non-Executive Independent Director for a term of five consecutive years.
The notice also details the procedures for remote e-voting, which commences on Friday, September 25, 2026, at 09:00 A.M. and concludes on Sunday, September 27, 2026, at 05:00 P.M. The record date for determining voting eligibility is Monday, September 21, 2026. Several notes provide extensive instructions for shareholders on how to participate in the AGM and cast their votes electronically.
A plain-language summary of a public exchange filing by Shukra Pharmaceuticals Limited. Read the original for the full detail.
